Amicus Therapeutics Announces Successful Completion Of End Of Phase 2 Meeting With FDA For Amigal In Fabry Disease

Amicus Therapeutics (Nasdaq: FOLD), a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of human genetic diseases, announced that it has successfully completed an End of Phase 2 meeting for Amigal(TM) with the U.S. Food and Drug Administration (FDA).

More: continued here

Filed under: Endocrinology on August 11th, 2008